Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Newer treatments for fibromyalgia syndrome

Authors Richard E Harris, Daniel J Clauw

Published 5 December 2008 Volume 2008:4(6) Pages 1331—1342

DOI http://dx.doi.org/10.2147/TCRM.S3396

Review by Single-blind

Peer reviewer comments 5

Richard E Harris, Daniel J Clauw

Department of Anesthesiology, The University of Michigan, Ann Arbor, MI, USA

Abstract: Fibromyalgia syndrome is a common chronic pain disorder of unknown etiology. The lack of understanding of the pathophysiology of fibromyalgia has made this condition frustrating for patients and clinicians alike. The most common symptoms of this disorder are chronic widespread pain, fatigue, sleep disturbances, difficulty with memory, and morning stiffness. Emerging evidence points towards augmented pain processing within the central nervous system (CNS) as having a primary role in the pathophysiology of this disorder. Currently the two drugs that are approved by the United States Food and Drug Administration (FDA) for the management of fibromyalgia are pregabalin and duloxetine. Newer data suggests that milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, may be promising for the treatment of fibromyalgia. A double-blind, placebo-controlled trial of milnacipran in 125 fibromyalgia patients showed significant improvements relative to placebo. Milnacipran given either once or twice daily at doses up to 200 mg/day was generally well tolerated and yielded significant improvements relative to placebo on measures of pain, patient’s global impression of change in their disease state, physical function, and fatigue. Future studies are needed to validate the efficacy of milnacipran in fibromyalgia.

Keywords: fibromyalgia, pain, pharmacological, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand

Chinwong D, Patumanond J, Chinwong S, Siriwattana K, Gunaparn S, Hall JJ, Phrommintikul A

Therapeutics and Clinical Risk Management 2015, 11:659-667

Published Date: 24 April 2015

Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials

Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P

Drug Design, Development and Therapy 2015, 9:1927-1936

Published Date: 1 April 2015

Decreased mean platelet volume in panic disorder

Göğçegöz Gül I, Eryılmaz G, Özten E, Hızlı Sayar G

Neuropsychiatric Disease and Treatment 2014, 10:1665-1669

Published Date: 4 September 2014

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

Inoue K, Fujimoto T, Higa R, Moriyama R, Kohmoto H, Nagumo H, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:771-775

Published Date: 21 May 2012

Compliance of the aorta in two diseases affecting vascular elasticity, familial hypercholesterolemia and diabetes: a MRI study

Sami Soljanlahti, Taina Autti, Laura Hyttinen, Alpo F Vuorio, Pekka Keto, Kirsi Lauerma

Vascular Health and Risk Management 2008, 4:1103-1109

Published Date: 10 October 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008

Perioperative hypertension management

Joseph Varon, Paul E Marik

Vascular Health and Risk Management 2008, 4:615-627

Published Date: 6 June 2008

Therapeutical approach to plasma homocysteine and cardiovascular risk reduction

Marcello Ciaccio, Giulia Bivona, Chiara Bellia

Therapeutics and Clinical Risk Management 2008, 4:219-224

Published Date: 8 February 2008